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Sharp-1 is a basic helix-loop-helix (bHLH) transcriptional repressor which is involved in a 24 
number of cellular processes. Our previous studies have demonstrated that Sharp-1 is a negative 25 
regulator of skeletal myogenesis and blocks differentiation of muscle precursor cells by 26 
modulating MyoD activity. In order to understand its role in pre- and post-natal myogenesis, we 27 
assessed skeletal muscle development, and freeze-injury induced regeneration in Sharp-1 28 
deficient mice. We show that embryonic skeletal muscle development is not impaired in the 29 
absence of Sharp-1, but post-natally, the regenerative capacity is compromised. Although the 30 
initial phases of injury induced regeneration proceed normally in Sharp-1-/- mice, during late 31 
stages, the mutant muscle exhibits necrotic fibers, calcium deposits, and fibrosis. TGF-β 32 
expression, as well as pSmad 2/3 levels are sustained in the mutant tissue, and treatment with 33 
decorin, a TGF-β blocker improves histo-pathology of Sharp-1-/- injured muscles. In vitro, 34 
Sharp-1 associates with Smad3, and its overexpression inhibits TGF-β and Smad3-mediated 35 
expression of extracellular matrix genes in myofibroblasts. These results demonstrate that Sharp-36 
1 regulates muscle regenerative capacity, at least in part, by modulation of TGF-β signaling. 37 

























Regeneration is a feature of postnatal skeletal muscle and occurs to replace damaged 40 
myofibers following exercise or injury (Hawke and Garry, 2001; Huard et al., 2002; Charge and 41 
Rudnicki, 2004). Regeneration of muscle is dependent on satellite cells, and can be divided into 42 
distinct phases, which include inflammation, tissue formation, and tissue remodeling. During the 43 
inflammatory phase, the damaged muscle tissue is infiltrated by immune cells, and activated 44 
macrophages play a key role in the removal of necrotic tissue. This is followed by tissue 45 
formation that is dependent on the proliferation and differentiation of satellite cells. Many 46 
growth factors and cytokines that are mitogenic for satellite cells have been implicated in this 47 
process (Husmann et al., 1996). The progeny of activated satellite cells called muscle precursor 48 
cells undergo multiple rounds of proliferation, withdraw from the cell cycle, and differentiate to 49 
form myotubes characterized by the presence of a centrally located nuclei (Huard et al., 2002; 50 
Charge and Rudnicki, 2004). Further growth and fusion results in the formation of myofibers. 51 
During tissue remodeling, fibroblasts present at the site of injury produce an initial extracellular 52 
matrix (ECM) of type I and type III collagens. Differentiation of fibroblasts into myofibroblasts 53 
augments their contractile activity (Border and Ruoslahti, 1992; Border and Noble, 1994; 54 
Grinnell, 1994). Myofibroblasts also produce ECM further contributing to tissue remodeling. 55 
Once the tissue is repaired, the contractile activity of myofibroblasts is terminated, and cells are 56 
removed by apoptosis. Myofibroblast persistence and excessive fibroblast proliferation can result 57 
in the formation of scar tissue (fibrosis) that is a sign of incomplete regeneration, and is often 58 
accompanied by elevated TGF-β levels and collagen deposition (Desmoulière et al., 1993; Serini 59 
et al., 1996; Serini et al., 1998). In myopathies such as Duchenne Muscular Dystrophy (DMD), 60 
the regeneration process is compromised, and muscle tissue is replaced by dysfunctional scar 61 
(fibrotic) tissue. TGF-β 1 and 2 levels are elevated in muscular dystrophies and have been shown 62 
to cause fibrosis in dystrophic muscles (Bernasconi et al., 1995; Bernasconi et al., 1999; 63 
Mutakami et al., 1999; Zhu et al., 2007). Interestingly inhibition of TGF-β signaling not only 64 
prevents fibrosis, but also improves regeneration in the mdx mutants that are widely studied as a 65 
mouse model for DMD (Lefaucheur and Sébille, 1995; Cohn et al., 2007) indicating that 66 
regulation of fibrosis presents a key step in the pathology of DMD. 67 
Members of the TGF-β superfamily are multifunctional cytokines that regulate diverse 68 
























apoptosis and cell cycle arrest (Barnard et al., 1990; Moses et al., 1990). In general, TGF-βs 70 
inhibit proliferation of most cells and induce apoptosis of epithelial cells. In contrast, TGF-β 71 
stimulates fibroblast cells to proliferate and produce ECM that results in a fibrotic response in 72 
tissues. TGF-β signals through heteromeric transmembrane type I and type II receptors (Wrana  73 
et al., 1992; Heldin et al., 1997). In presence of TGF-β ligand, the receptor activated Smads i.e. 74 
Smad2 and Smad3, are phosphorylated, bind to the common Smad (Smad4) and translocate into 75 
the nucleus (Wrana  et al., 1992; Massagué et al., 1997). Nuclear Smad protein complexes bind 76 
specific DNA sequence motifs and recruit coactivators such as CBP/p300 and participate in 77 
transcriptional regulation of target genes (Massagué et al., 1997) including those encoding ECM 78 
proteins. Excessive TGF-β-induced deposition of ECM at the site of injury can lead to fibrosis 79 
(Serini et al., 1996; Serini et al., 1998). While several pathways are implicated in regulation of 80 
the distinct steps in muscle regeneration, the molecular mechanisms governing regeneration and 81 
repair are not fully understood.   82 
Sharp-1/Dec2, a basic helix-loop-helix transcription factor plays complex roles in cellular 83 
differentiation, apoptosis, cell cycle arrest, tumor progression and circadian rhythms (Yamada 84 
and Miyamoto, 2005; Sun et al., 2007a). Our previous studies have shown that overexpression of 85 
Sharp-1 in myoblasts or preadipocytes blocks their ability to undergo terminal differentiation 86 
(Azmi et al., 2004; Gulbagci et al., 2009; Ling et al., 2012; Wang et al., 2013). Here, we 87 
demonstrate that Sharp-1 plays a role in skeletal muscle regeneration via regulation of TGF-β 88 
signaling. In response to injury, Sharp-1 null mutants exhibit a defect at late stages of 89 
regeneration. Sustained TGF-β expression, increased pSmad2/3 levels, and smooth muscle actin 90 
(SMA+) positive myofibroblasts are evident in Sharp-1-/- regenerating tissue. Inhibition of TGF-91 
β signaling ameliorates muscle pathology and degeneration in Sharp-1-/- mice. We demonstrate 92 
that Sharp-1 directly regulates TGF-β signaling and antagonizes Smad3-dependent expression of 93 
collagens and tissue inhibitor of metalloproteinase 1 (TIMP1) likely via interaction with Smad3 94 
and inhibition of its transcriptional activity. Taken together, our studies indicate that Sharp-1 is 95 































Skeletal muscle development in Sharp-1-/- mice 104 
We have previously demonstrated that Sharp-1 is expressed in skeletal muscles during 105 
embryonic development as well as in adult tissues, and its overexpression inhibits myogenesis 106 
through regulation of MyoD activity (Azmi and Taneja, 2003; Azmi et al., 2004; Ling et al., 107 
2012; Wang et al., 2013). To further examine the role of endogenous Sharp-1 we analyzed 108 
embryonic and postnatal myogenesis in wild type (WT) and littermate Sharp-1 null (Sharp-/-) 109 
mutants (Rossner et al., 2008). No overt difference in myogenin expression was apparent in WT 110 
and Sharp-1 null embryos at embryonic (E) day 16.5 (Fig 1A). Histological analysis of 111 
quadriceps muscles from adult WT and Sharp-1-/- mice also did not reveal obvious defect in 112 
muscle architecture (Fig 1B) or in the mean cross section area (CSA) (Fig 1C, right panel) 113 
indicating that  the development of skeletal muscles occurs normally in the absence of Sharp-1. 114 
Moreover, no changes in the number of Pax7+ satellite cells was noted between WT and Sharp-1-115 
/- mutants (Fig 1D & E).  116 
 117 
Skeletal muscle regeneration is impaired in Sharp-1 null mutants 118 
We then examined the regenerative potential of Sharp-1 null mutants in response to 119 
freeze injury. Quadriceps muscles from 2-3 month old WT and Sharp-1-/- mice were injured 120 
(Sun et al., 2007b) and regeneration was analyzed histologically.  Hematoxylin & Eosin (HE) 121 
staining of injured muscle sections revealed extensive myofiber damage in both WT and Sharp-122 
1-/- mice at  D2, with no marked histological differences apparent at this stage (data not shown). 123 
Five days after injury (D5), regeneration was evident in both WT and Sharp-1-/- muscles with 124 
the presence of newly formed myotubes containing central nuclei (Fig 2A).  Ten and sixteen 125 
days (D10 and D16 respectively) post injury, regeneration in WT mice was evident by presence 126 
of centrally nucleated newly formed myotubes. In contrast to WT muscles, the mutant tissue 127 
revealed overt signs of necrosis and degeneration (Fig 2A). Indeed, mutant quadriceps muscles 128 
























2B). In addition, fibrosis was detectable in the mutant regenerating muscles by Masson’s 130 
Trichrome staining (Fig 2C).  131 
To examine the mechanisms underlying defective regeneration in Sharp-1-/- muscle,  we 132 
first analyzed the expression of MyoD, a marker of proliferating myoblasts. MyoD levels were 133 
upregulated during regeneration in both WT and Sharp-1-/- mutants as seen by western blot 134 
analysis (Fig 3A). Immunostaining of D10 injured tissue revealed many MyoD+ cells in the 135 
mutant tissue compared to WT muscle. Moreover, several smooth muscle actin positive (SMA+),  136 
cells were also apparent in Sharp-1-/- muscle that did not co-localize with MyoD+ cells 137 
indicating presence of myofibroblasts in the mutant tissue (Fig 3B). We then examined 138 
differentiation using embryonic MHC (eMHC) antibody. Immunostaining of injured WT and 139 
Sharp-1-/- muscles at D5 revealed a higher number of eMHC+ myotubes in the mutant tissue that 140 
correlated with a higher regeneration index (Fig 3C &D). Together these results suggest the 141 
compromised regeneration at late stages (D10/D16) is not due to a differentiation defect, but may 142 
reflect an additional role for Sharp-1 in late steps of tissue remodeling. 143 
 144 
Increased TGF-β signaling in Sharp-1-/- injured muscles  145 
On activation by ligand, TGF-β receptors induce phosphorylation of Smad2 and Smad3 146 
(pSmad2/3), which form a heterotrimeric complex with Smad4 and then translocate to the 147 
nucleus (Wrana et al., 1992). Estimation of pSmad2/3 levels thus serves as a measure of TGF-β 148 
signaling. Since Sharp-1-/- mutants exhibited fibrosis, we examined TGF-β expression levels by 149 
western blot analysis in WT and Sharp-1-/- muscles at various time points after injury (Fig 4A). 150 
In WT mice, TGF-β expression was strongly induced upon injury with elevated levels apparent 151 
at D2, and the levels started to decline at D5 and D10. In contrast, TGF-β expression was 152 
sustained at high levels at D5 and D10 in Sharp-1 null mutants. To examine whether the 153 
increased TGF-β resulted in increased signaling, we analyzed pSmad2/3 levels by 154 
immunostaining (Fig 4B). Interestingly, in correlation with increased TGF-β levels, pSmad2/3 155 
levels were also higher in Sharp-1-/- injured muscles at D5 and D10 compared to WT muscles 156 
(Fig 4B). TGF-β induces differentiation of myofibroblasts that play a critical role in fibrosis 157 
(Desmoulière et al., 1993; Li et al., 2004). Consistent with sustained high levels of TGF-β 158 
























injury (Fig 4C) which was in contrast to WT tissue where few SMA+ myofibroblasts were 160 
apparent at any stage.  161 
 162 
Inhibition of TGF-β  signaling ameliorates muscle necrosis 163 
Previous studies have demonstrated that blocking TGF-β can improve muscle pathology 164 
in mdx mice (Cohn et al., 2007) and one such blocker which has been successfully used against 165 
fibrosis in mice is the proteoglycan, decorin (Isaka et al., 1996; Li et al., 2007). To assess 166 
whether the enhanced TGF-β signaling underlies muscle necrosis in Sharp-1-/- mice, we injected 167 
decorin in Sharp-1-/- muscle and performed histological analysis three days later. The 168 
contralateral muscle was injected with PBS. Decorin injected injured muscles from Sharp-1-/- 169 
mice showed a considerable decrease in degenerating myofibers and significant increase in 170 
regenerating myofibers (Fig 5A). Quantification of the damaged area indicated reduced 171 
pathology in decorin injected muscles relative to uninjected muscle (Fig 5B). To further confirm 172 
that decorin indeed led to reduced TGF-β signaling, uninjected and injected injured muscles 173 
were immunostained with pSmad2/3 antibody (Fig 5C). As expected, pSmad2/3 staining was 174 
higher in uninjected tissue compared to one injected with decorin. Moreover, consistent with 175 
inhibition of TGF-β activity, SMA+ cells were also reduced in decorin treated muscle (Fig 5D). 176 
  177 
Sharp-1 regulates TGF-β signaling 178 
To examine the mechanisms that might account for de-regulated TGF-β expression and 179 
signaling, we first investigated whether Sharp-1 interacts with components of the pathway. The 180 
interaction of Sharp-1 with Smad3, a key mediator of TGF-β response was analyzed.  Myc-181 
Sharp-1 was transfected in cells and lysates were harvested in the absence and presence of TGF-182 
β treatment. An interaction of Sharp-1 with endogenous pSmad2/3 and total Smad2/3 was 183 
apparent in the presence of TGF-β (Fig 6A). To define the domains in Sharp-1 that associate 184 
with Smad3, various Sharp-1 deletion mutants (Ling et al., 2012) were transfected alone or 185 
together with Smad3. Immunoprecipitation assays indicated that full length Sharp-1, and the 186 
deletion mutants Sharp-1∆C, lacking the C-terminal region, and Sharp-1∆O, devoid of the 187 
orange domain, interacted with Smad3. However no association was seen with the Sharp-1-188 
bHLH mutant, which lacks the bHLH domain indicating that the region essential for interaction 189 
























localized with Smad3 in the presence of TGF-β (Fig 6C). To determine if Sharp-1 directly 191 
interacts with Smad3, we performed GST-pull down assays. Equivalent amounts of GST-Sharp-192 
1 or GST protein alone were incubated with 35S labeled Smad3. Sharp-1 directly interacted with 193 
Smad3, while as expected, no interaction of Smad3 was apparent with GST protein (Fig 6D).  194 
We next investigated the effect of Sharp-1 expression on TGF-β and Smad3-dependent 195 
transcriptional responses using 3TP-Lux reporter, which contains a TGF-β response element 196 
from plasminogen activator inhibitor-1 (PAI-1) promoter and has been widely used to monitor 197 
TGF-β and Smad signaling (Wrana et al., 1992). Co-expression of full length Sharp-1 resulted in 198 
repression of Smad3-induced reporter activity. In contrast, the Sharp-1-bHLH mutant, which 199 
failed to interact with Smad3, was significantly less effective in repression of Smad3-dependent 200 
transcriptional activity (Fig 7A). Conversely, reporter activity was increased in cells transfected 201 
with Sharp-1 siRNA (siSharp-1) relative to control cells transfected with scrambled siRNA 202 
(siRNA) validating that endogenous Sharp-1 regulates Smad3 activity (Fig 7B). To examine the 203 
mechanisms underlying the inhibitory effect of Sharp-1 on Smad3 activity, we investigated 204 
whether Sharp-1 impacts the ability of Smad3 to bind to a Smad binding element (SBE). Flag-205 
Smad3 and Flag-Smad4 were transfected in the absence or presence of Myc-Sharp-1. Nuclear 206 
extracts were incubated with a radioactive SBE probe. A complex containing Smad3/4 was 207 
evident on SBE, that was supershifted with anti-Flag, but not with anti-Myc antibody (Fig 7C). 208 
Together, these data demonstrate that Sharp-1 does not directly bind to SBE, nor does it alter 209 
binding of Smads to SBE.  210 
Myofibroblasts which are heterogenous in origin, play a key role in tissue remodeling and 211 
are characterized by synthesis of extracellular matrix (ECM) proteins and expression of SMA.  212 
Differentiation of fibroblast and other cells to myofibroblasts requires TGF-β signaling which 213 
results in expression of ECM genes such as collagen1A1 (COL1α1), collagen1A2 (COL1α2), 214 
and collagen3A1 (COL3α1) in a Smad3-dependent manner. In addition, TGF-β inhibits ECM 215 
degradation by increasing expression of matrix metalloprotease inhibitors such as tissue inhibitor 216 
of metalloprotease (TIMP-1). Given the increased TGF-β signaling and SMA+ cells in Sharp-1 217 
injured muscle, and the ability of Sharp-1 to antagonize Smad3 activity, we sought to determine 218 
whether Sharp-1 regulates TGF-β induced ECM gene expression in myofibroblasts. NIH3T3 219 
fibroblast cells that inducibly express Sharp-1 (Liu et al., 2010) were treated with TGF-β. As 220 
























Interestingly, induction of Sharp-1 with doxycycline significantly inhibited TGF-β mediated 222 
expression of COL1α1, COL3α1 and TIMP-1 (Fig 7D). Similar results were seen when cells 223 
were treated with TGF-β for 48hr (data not shown). The basal expression of COL1α1, and 224 
COL3α1 were suppressed by Sharp-1 even in the absence of exogenous TGF-β indicating an 225 
impact of Sharp-1 on endogenous Smad3 activity. Moreover, chromatin immunoprecipitation 226 
assays showed that both Sharp-1 and Smad3 were present promoters of plaminogen activator 227 
inhibitor PAI-1 which plays a significant role in fibrosis, and SMA, in a TGF-β responsive 228 
manner (Fig 7E).  Taken together, these results provide evidence that Sharp-1 antagonizes TGF-229 
β signaling likely via association with Smad3, and inhibition of its transcriptional activity in 230 


























The results of this study demonstrate a novel role for Sharp-1 in tissue remodeling and 234 
muscle regeneration via its ability to limit TGF-β signaling in myofibroblasts. While embryonic 235 
myogenesis does not appear to be overtly perturbed in Sharp-1-/- embryos, differentiation of 236 
myogenic precuror cells in response to injury is enhanced. Interestingly however, despite 237 
productive differentiation, Sharp-1-/- mice show a regeneration defect at late stages characterized 238 
by myonecrosis, proliferating myogenic and non-myogenic cells, calcification, and fibrosis.     239 
Postnatal myogenesis involves the interplay of many growth factors and cytokines, which 240 
act as positive or negative regulators of regeneration (Husmann  et al., 1996; Charge and 241 
Rudnicki, 2004). One such negative regulatory factor is TGF-β. TGF-β has been reported to 242 
inhibit myoblast proliferation and myogenic differentiation by inhibition of MyoD (Massague et 243 
al., 1986; Allen and Boxhorn, 1987; Liu et al., 2001). Moroever, TGF-β also induces 244 
differentiation of fibroblasts into myofibroblasts in injured skeletal muscle (Li et al., 2004). The 245 
resulting overproliferation of myofibroblasts underlies deposition of extracellular matrix proteins 246 
resulting in fibrosis and hindering complete regeneration of muscle tissue.  247 
TGF-β expression and signaling are sustained at high levels in the mutants during 248 
regeneration. Intriguingly however, myogenic differentiation is augmented at early stages in 249 
Sharp-1 mutant tissue as seen by the increased number of eMHC+ cells. This may likely occur as 250 
Sharp-1 is a potent inhibitor of MyoD activity and myogenic differentiation (Azmi et al., 2004; 251 
Morosetti et al., 2006; Ling et al., 2012; Wang et al., 2013). Its absence therefore would 252 
presumably result in increased MyoD activity that may counter inhibitory effects of TGF-β at 253 
early stages in Sharp-1-/- mutants. Sustained TGF-β levels at a step subsequent to myogenic 254 
differentiation, likely result in increased SMA+ myofibroblasts and fibrosis seen in the mutant 255 
tissue. Previous studies have demonstrated that TGF-β neutralizing antibodies and blockers can 256 
be used as potential antifibrotic agents (Isaka et al., 1996; Li et al., 2007). Blockade of TGF-β 257 
with decorin indeed resulted in nearly 35% decrease in myonecrosis in Sharp-1-/- mice. 258 
Therefore, enhanced TGF-β expression and signaling accounts at least in part, for defective 259 
regeneration in Sharp-1-/- muscle.  260 
Consistent with our findings, recent studies have shown an inverse correlation between 261 
Sharp-1 expression and TGF-β activity in breast and prostate cancer (Montagner et al., 2012; 262 
























mechanisms underlying its inhibitory effect have not been reported. TGF-β signaling and Smad3 264 
play a central role in fibrosis by enhancing expression of ECM genes such as collagens, 265 
decreasing expression of MMPs and increasing expression of MMP inhbitors (Flanders, 2004). 266 
Our data demonstrates that Sharp-1 directly interacts with Smad3, and inhibits its transcriptional 267 
activity. This antagonism is not due to direct competition for DNA-binding as Sharp-1 does not 268 
bind to the Smad binding sites, nor does it impact binding of Smads to DNA.  It is plausible that 269 
Sharp-1 may recruit co-factors such as HDAC1 (Garriga-Canut et al., 2001), Sirt1 (Fujimoto et 270 
al., 2007) or G9a (Ling et al., 2012; Wang et al., 2013) to block Smad3 transcriptional activity in 271 
a cell type specific manner.  272 
Fibrosis poses a major obstacle to therapy not only in muscle diseases, but several other 273 
tissues as well. While the role of TGF-β signalling in fibrosis is well established, much remains 274 
to be understood with regard to the mechanisms that lead to inappropriate TGF-β signaling and 275 
development of fibrosis. Our studies provide novel insights into the role of Sharp-1 in controlling 276 

























Material and methods 279 
Regeneration of skeletal muscle: Sharp-1-/- mice have been described (Rossner et al., 2008). 280 
Freeze-crush injury induced regeneration was performed as described (Sun et al., 2007b). At 281 
least 4 mice were analyzed per time point (2, 5, 10, and 16 days after injury). All animal 282 
protocols followed institutional guidelines. For TGF-β blockade in vivo, quadriceps muscles 283 
were injured as described above. Seven days after injury, 20 ul (50 µg) of decorin (Sigma, St. 284 
Louis, MO, USA) was injected at 6 sites as described (Li et al., 2004). PBS (in 0.1% BSA) was 285 
injected as a control in the contralateral injured muscle. Muscles were collected three days after 286 
decorin injection and analyzed histologically.  287 
Antibodies: Anti-MyoD and anti-pSmad2/3 antibodies used for immunohistochemistry were 288 
from SantaCruz, Dallas, Texas, USA; anti-TGF-β was from Novocastra, Buffalo Grove, IL, 289 
USA; anti β-actin from Sigma, St. Louis, MO, USA; anti-EF1α  from Upstate Biotechnology 290 
Inc., Lake Placid, NY USA; anti-Pax7 and anti-eMHC from Developmental Studies Hybridoma 291 
Bank; anti-SMA from Sigma, St. Louis, MO, USA, anti phospho-Smad2/3 (Ser465/467) 292 
antibody from Millipore, Billerica, MA, USA; anti-mouse and anti-rabbit alexafluor secondary 293 
antibodies from Molecular Probes, Eugene, OR, USA; anti-mouse and anti-rabbit HRP 294 
conjugated secondary antibodies from Sigma, St. Louis, MO, USA.  295 
Histology and immunohistochemistry: Serial cross-sections (8 µm thick) were collected along 296 
the entire length of embedded muscle tissues, and one out of every ten slides was stained with 297 
hematoxylin and eosin (HE) for identification of the largest damaged area. Sections from both 298 
genotypes with comparable damaged area were used for histology and immunohistochemistry. 299 
Immunohistochemistry was performed as described previously (Sun et al., 2001) and visualized 300 
using the VECTASTAIN Elite ABC kit (Vector Laboratories, Burlingame, CA, USA). Staining 301 
without primary antibody served as a negative control. For immunofluorescence, paraffin-302 
embedded sections were incubated with appropriate primary antibody followed by detection with 303 
secondary antibody from Alexafluor and analysed under fluorescence microscope. Masson’s 304 
Trichrome staining was performed using a kit (Diagnostics Biosystem, Pleasanton, CA, USA). 305 
For alizarin red staining, sections were deparaffinized and stained for 30 seconds in 2% alizarin 306 
red solution followed by washes in acetone, acetone:xylene (1:1), xylene and mounted. Calcium 307 
























Morphological analysis: Damaged area and cross section area (CSA, µm2) were measured using 309 
ImageJ software (version 1.36b, NIH). For measuring CSA, quadriceps from 4 mice (3 month 310 
old) of each genotype were analysed and at least 500 myofibers per muscle were measured. The 311 
extent of pathology with or without decorin treatment was determined as a ratio of the necrotic 312 
area of the injured muscle to the total area of the injured muscle section. 313 
Regeneration index: Regeneration was assessed by counting the number of eMHC+ fibers 314 
normalized to the total number of nuclei in 5-10 randomly selected fields as described previously 315 
(Sun  et al., 2007b).  316 
Satellite cell number:  Paraffin sections of quadriceps muscle from two-month old mice were 317 
stained with anti-Pax7 antibody and counter stained with hematoxylin. Both myonuclei and 318 
Pax7+ nuclei were counted from several random fields for each animal, and the percentage of 319 
satellite cells was calculated. At least 500 nuclei were counted for each animal, and the data 320 
presented are an average of four animals.  321 
Immunofluorescence analysis:  Paraffin embedded sections were deparaffinised in histoclear. 322 
After antigen retrieval sections were incubated in blocking buffer for 1hr, followed by staining 323 
with primary antibodies to SMA and MyoD and detection with  alexa flour dye conjugated 324 
secondary antibodies. Sections were mounted in DAPI containing mounting medium, 325 
Vectashield H-1200, (Vector Laboratories, Burlingame, CA, USA) and imaged using Zeiss 326 
AX10 microscope. To determine localization of Sharp-1 and Smad3, C2C12 cells were seeded in 327 
chamber slides at ~30% confluence. Cells were transfected with Myc-Sharp-1, Flag-Smad3 328 
alone or together. 24hr after transfection, cells were fixed in 4% paraformaldehyde, treated with 329 
0.5 % Triton-X 100 and washed with PBS. After blocking (10% BSA in PBS), slides were 330 
incubated with Myc and Flag antibodies followed by fluorescence conjugated secondary 331 
antibodies. Cells were mounted in DAPI containing mounting medium from Vectastain, Vector 332 
Laboratories, Burlingame, CA, USA and viewed under a fluorescence microscope.   333 
Plasmids, cell culture, luciferase assays and Sharp-1 knockdown: Flag-Smad2, Flag-Smad3, 334 
and Flag-Smad4 were kindly provided by Rik Derynck; 3TP-Lux was kindly provided by Jeff 335 
Wrana; Myc-Sharp-1 and GST-Sharp-1 have been described (Ling et al., 2012). C2C12 and 336 
293T cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 20% 337 
























DMEM with 2% horse serum. NIH3T3 cells were maintained in DMEM containing 10% bovine 339 
serum (BS). Sharp-1 inducible NIH3T3 cells have been described and were treated with 2µg/ml 340 
doxycycline (DOX) for 24 and 48 hr to induce Sharp-1 (Liu et al., 2010). Transient transfections 341 
were performed using Lipofectamine Plus or Lipofectamine 2000 (Invitrogen, Grand Island, NY, 342 
USA). For reporter assays, cells were transfected with the reporter 3TP-Lux and various plasmid 343 
constructs as indicated in the figures along with 5ng of Renilla Luciferase as an internal control. 344 
Empty expression vector was added to normalize the amount of total DNA. 48 hr post-345 
transfection, luciferase assays were performed using the dual luciferase system (Promega, 346 
Fitchburg, WI, USA). All transfections were performed in triplicates and repeated at least twice. 347 
Values are reported as means with standard deviation (SD). To knockdown Sharp-1, C2C12 cells 348 
were transfected with 100nM siRNA specific for mouse Sharp-1 (Qiagen, Valencia, CA), or with 349 
control scrambled siRNA using Lipofectamine RNAiMAX (Invitrogen, Grand Island, NY, 350 
USA). 24 hr post-transfection, siRNA knockdown cells were transfected with the reporter and 351 
plasmid constructs and luciferase activity was measured as described above. For all experiments, 352 
TGF-β was used at 5ng/ml. 353 
Co-immunoprecipitation (Co-IP) and GST-pull down assays: Co-IP and GST-pull down 354 
assays were done as described (Sun and Taneja, 2000). Briefly, for Co-IP assays, cells were 355 
transfected with Myc Sharp-1.  24hr later, cells were treated for 1hr with 5ng/ml TGF-β before 356 
lysing. Control cells were not treated with TGF-β. Sharp-1 was immunoprecipated using Myc-357 
agarose beads (Sigma, St. Louis, MO, USA) and probed for endogenous pSmad2/3  and Smad3. 358 
To map the interaction domains between Sharp-1 and Smad3, cells were transfected with full 359 
length Myc-Sharp-1 and deletion mutants Sharp-1 bHLH, Sharp-1 ΔO or Sharp-1 ΔC  (Ling et 360 
al., 2012) together with Flag-Smad3. 48hr later, cells were washed twice with cold PBS, lysed in 361 
50 mM Tris-HCl pH8.0, 50 mM NaCl, 1mM EDTA, 0.1% Triton X-100, 0.5 mM PMSF and 362 
protease inhibitors (Roche Applied Science , Mannheim, Germany). Equal amounts of total 363 
protein were loaded for western blotting. Lysates were incubated with Flag-agarose beads 364 
(Sigma, St. Louis, MO, USA) and analyzed by western blotting using anti-Myc antibody (1:1000   365 
Sigma, St. Louis, MO, USA). For GST-pull down assays, Smad3 was translated in vitro and 366 
labeled with 35S-methionine using the TNT-coupled reticulocyte lysate system (Promega, 367 
Fitchburg, WI, USA). 35S-labeled Smad3 was incubated with purified GST-Sharp-1 or GST in 368 
























2000).  370 
Electrophoretic Mobility Shift Assay (EMSA): Flag-Smad3, Flag-Smad4 and Myc-Sharp-371 
1were transfected and 48 hr later, cells were stimulated with TGF-β (5ng/ml) for 1hr.  Nuclear 372 
extracts prepared from transfected samples were incubated with 32P-labeled SBE probe (5’-373 
CTCTATCAATTGGTCTAGACTTAACCGGA) (Luo et al., 1999). Binding reactions contained 374 
40,000 cpm probe, 1 µg of poly(dI-dC), 10mM HEPES, pH 7.9, 80mM KCl, 0.1 mM EDTA, 375 
5mM MgCl2, 0.5 mM dithiothreitol, 10% glycerol and increasing amounts of nuclear extract (+ 376 
1.5µg; ++  3µg). The reaction was incubated in room temperature for 20min and fractionated on 377 
5% polyacrylamide gels. For supershift, antibodies were added and incubated for 10min 378 
following incubation with radiolabeled probe.  379 
Chromatin Immunoprecipitation assay: C2C12 cells at 80% confluency were cultured in 380 
differentiation medium for 2 days in the absence or presence of 5ng/ml TGF-β. Cells were fixed 381 
with 1% formaldehyde and ChIP assays were performed using Millipore ChIP kit (Billerica, 382 
Massachusetts).  2ug of anti-Sharp-1 and anti-Smad3 antibodies (SantaCruz, Dallas, Texas  383 
USA) were used. DNA was amplified by QRT-PCR ((Roche Applied Science , Mannheim, 384 
Germany) with primers specific to mouse PAI-1 promoter (-600 to -800bp) containing 385 
TGFβ/SMAD responsive regions. Primer sequences for mouse PAI-1 are: 5’ 386 
CACAAAGAGCGAGCCCTCAG-3’ and 5’-CCAGAGGGCATGAAATGTGC-3’. Primers for 387 
SMA promoter have been described previously (Elberg et al., 2008). 388 
Quantitative real time PCR (Q-PCR). Q-PCR was done as described (Ling et al., 2012). 389 
Briefly, RNA was reverse transcribed using iSCRIPT (Biorad, Hercules, California, USA) and 390 
Q-PCR was performed using Roche Sybr green in LC480 (Roche Applied Science , Mannheim, 391 
Germany). Mouse Sharp-1 was amplified using the following primers: Forward 5’-392 
AACACTGGGGCATTTGGAGA-3’ and Reverse 5’-TGGACCGGCGATTTCAGAG-3’. 393 
Primers for TIMP-1, COL1α1 and COL3α1 have been  described previously (Meng et al., 2010; 394 
and Uezumi et al., 2011). 395 
Statistical analysis: Student t-test was used to perform statistical analysis and p values of <0.05 396 
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Figure Legends: 557 
Figure 1: Skeletal muscle development in Sharp-1-/- mutants.  558 
(A) Embryonic myogenesis in WT (+/+) and Sharp-1-/- (-/-) embryos at E16.5 was analyzed by 559 
immunostaining with anti-myogenin antibody followed by fluorescence microscopy. (B) 560 
Quadriceps muscles from 2 month old WT (+/+) and Sharp-1-/- (-/-) mice (n=4) were analyzed 561 
histologically by H&E staining. (C) H&E stained sections of quadriceps muscles were used to 562 
determine the cross-section area of myofibers in both genotypes (n=4). The mean fiber size was 563 
not significantly different between WT and Sharp-1-/- mice.  Data are mean ± standard error. (D) 564 
3 week old WT (+/+) and Sharp-1-/- (-/-) muscles were immunostained with anti-Pax7 antibody 565 
to detect satellite cells. Sections were counterstained with hematoxylin. (E) Pax7 stained muscle 566 
sections were used to analyse the percentage of satellite cells from four independent WT (+/+) 567 
and Sharp-1-/- (-/-) mice.  Scale bar: 100 µm. 568 
Figure 2: Altered regenerative response upon freeze injury in Sharp-1-/- mice.  569 
 (A) Histological analysis of muscle regeneration in WT (+/+) and Sharp-1-/- (-/-) mice at D5, 570 
D10 and D16 following injury. At D5, newly formed myotubes with central nuclei are evident in 571 
both WT and mutant muscles. At later stages (D10 and D16 after injury), muscle degeneration is 572 
apparent in Sharp-1-/- mutants. (B, C) Alizarin red staining (B), and Masson’s Trichrome 573 
staining (C), at D16 after injury revealed the presence of calcium deposits and collagen 574 
deposition (blue staining) respectively in Sharp-1-/- muscles. Scale bar: 100 µm.  575 
Figure 3: Myogenic differentiation is not altered in Sharp-1-/- muscles.  576 
(A) Western blotting was performed with protein lysates from WT (+/+) and Sharp-1-/- (-/-) 577 
uninjured (D0) and injured tissues (D2, D5 and D10 after injury) to detect MyoD expression.  578 
EF1α was used as an internal control. (B) Sections of quadriceps muscles from WT (+/+) and 579 
Sharp-1-/- (-/-) mice at D10 after injury were immunostained with anti-MyoD and anti-SMA 580 
antibodies. (C) Sections of quadriceps muscles from WT (+/+) and Sharp-1-/- (-/-) mice at D5 581 
after injury were stained with anti-eMHC antibody. (D) Regeneration index was calculated by 582 
determining the percentage of eMHC+ myotubes in WT and Sharp-1-/- mice (n=4). Data are 583 
mean±standard error.  584 
Figure 4: Increased TGF-β and pSmad2/3 levels in Sharp-1-/- regenerating tissue.  585 
(A) Western blotting was performed with protein extracts from WT and Sharp-1-/- regenerating 586 
























used as an internal control. (B-C) Sections of injured muscles from WT and Sharp-1-/- mice 588 
were immunostained with antibodies against pSmad2/3 (B), and SMA (C) at D5, and D10 after 589 
injury.  590 
Figure 5: Inhibition of pSmad signaling reduces muscle necrosis in Sharp-1-/- mutants.  591 
(A) Decorin, or the control vehicle (PBS) was injected in Sharp-1-/- muscles seven days after 592 
injury, and cross sections were analyzed at D10 by H&E staining. Decorin injected muscles 593 
show a striking reduction of muscle pathology compared to the contralateral injured muscles 594 
(n=4) that were injected with PBS. (B) The percentage of pathology in the absence and presence 595 
of decorin was determined as a ratio of the necrotic area to the total injured area of the muscle. 596 
Results shown are representative from 4 sets of mice. Data are mean ± SD. (C-D) Control and 597 
decorin injected sections were immunostained with anti-pSmad2/3 (C) and anti-SMA (D) 598 
antibodies which revealed reduced pSmad2/3 signaling in decorin injected muscles (n=3). Bar: 599 
100 µm. 600 
Figure 6: Sharp-1 interacts with Smad3.   601 
(A) C2C12 cells were transfected with expression vectors for Myc-Sharp-1. Cells were left 602 
untreated or treated with TGF-β1 for 1hr. Lysates were immunoprecipitated with anti-myc 603 
agarose beads and immunoblotted with anti-pSmad2/3, Smad3 and myc antibodies. Input shows 604 
expression of Smad3 and Sharp-1 in the lysates. (B) Cells were transfected with plasmids 605 
expressing Flag-Smad3 and Myc-Sharp-1, Myc-Sharp-1 bHLH, Myc-Sharp-1 ΔO or Myc-Sharp-606 
1 ΔC. 48 hr after transfection, lysates were immunoprecipitated with flag agarose beads followed 607 
by western blot with anti-Myc antibody. Input shows expression of Smad3 and Sharp-1 in 608 
lysates. β actin was used as an internal control. *NS refers to a non-specific IgG band. (C) 609 
C2C12 cells co-transfected with Flag-Smad3 and Myc-Sharp-1 were analyzed using anti-Flag 610 
and anti-Sharp-1 antibodies. Nuclei were stained with DAPI. (D) Equivalent amounts of GST-611 
Sharp-1 or GST alone were incubated with 35S labeled in vitro translated Smad3. 10% of input 612 
was run on the gel as a control.  613 
Figure 7: Sharp-1 inhibits TGF-β  signaling in myofibroblasts. (A) Cells were transfected 614 
with reporter p3TP-Lux (200 ng) together with Smad3 (100ng) in the absence and presence of 615 
Sharp-1 (25ng) and Sharp-1 bHLH (25ng) as indicated. Cells were harvested 48 hr after 616 
transfection, and assayed for luciferase activity. Error bars indicate mean ± SD. (B) Cells were 617 
























Sharp-1 cells were transfected with p3TP-Lux (200 ng) with Smad3 (100ng) as indicted in 619 
figure. 24hr later, luciferase activity was assayed. Error bars indicate mean ± SD. (C) 32P-labeled 620 
SBE oligonucleotide was incubated with nuclear extracts prepared from non-transfected  cells 621 
(lanes 1, 2), increasing amount of Flag-Smad3/4 (lanes 3, 4), and increasing amount of Smad3/4 622 
and Myc-Sharp-1 (lanes 5, 6). Supershift assays were done with anti-Flag (lane 7) and anti-Myc-623 
antibodies (lanes 7 and 8). (D) NIH3T3 cells were left uninduced or induced with doxycycline 624 
(DOX) and treated with TGF-β for 24 hr. The expression of COL1α1, COL3α1 and TIMP-1 was 625 
analyzed by Q-PCR. (E) ChIP assays were performed to determine occupancy of Sharp-1 and 626 
Smad2/3 at the PAI-1 and SMA promoters in the absence and presence of TGF-β. Error bars 627 
indicate mean±SD. 628 
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